Oorsprong van het eerstegraads netwerk van Sandage Bobby
Entiteit | Type entiteit | Industrie | |
---|---|---|---|
SanaRx Biotherapeutics, Inc.
SanaRx Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology SanaRx Biotherapeutics, Inc. is a biotechnology company. It serves patients with orphan diseases of the alimentary tract. The company is headquartered in Medford, MA.
7
| Holding Company | Pharmaceuticals: Major | 7 |
Grafiek van bedrijven verbonden in de tweede graad
Connectie in verschillende bedrijven
Bedrijven verbonden met Sandage Bobby via zijn persoonlijke netwerk
Onderneming | Sector | Gelieerde personen | Hoofdpost |
---|---|---|---|
NextRNA Therapeutics, Inc.
NextRNA Therapeutics, Inc. BiotechnologyHealth Technology NextRNA Therapeutics, Inc. is a biotechnology company that specializes in drug development services. The company is based in Cambridge, MA. The company was founded in 2021 by Leon Wert-Lamas, Marc A. Cohen, Julia Novina, Carl Novina, Dominique Verhelle, Kenneth C. Anderson, Robert S. Langer. Dominique Verhelle has been the CEO since 2021. | Biotechnology | Director/Board Member Director/Board Member Founder Founder | |
Microbial Machines, Inc. | Chief Executive Officer Founder | ||
Pear Tree Pharmaceuticals, Inc.
Pear Tree Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Pear Tree Pharmaceuticals, Inc. operates as a development stage company with interests in developing prescription products for women. It offers products that treat and prevent diseases, symptoms, and conditions associated with menopause and cancer chemotherapy. The company was founded by Stephen Charles Rocamboli, Fred H. Mermelstein, Janet Chollet and Martin J. Driscoll in July 2007 and is headquartered in Auburndale, MA. | Pharmaceuticals: Major | Founder | |
The Rogosin Institute, Inc.
The Rogosin Institute, Inc. Medical/Nursing ServicesHealth Services The Rogosin Institute, Inc. engages in providing treatment for kidney diseases. The company was founded in 1983 and is headquartered in New York, NY. | Medical/Nursing Services | Director/Board Member | |
NX Development Corp.
NX Development Corp. Medical SpecialtiesHealth Technology NX Development Corp. operates as a life science company. It develops Gleolan oral solutions which helps in identifying malignant glioma, a type of brain tumor in adult patients. It allows surgeons to visualize brain tumors during surgery. The company was founded by Alan Ezrin and is headquartered in Lexington, KY. | Medical Specialties | Director/Board Member | |
CANDEL THERAPEUTICS, INC. | Biotechnology | Director/Board Member | |
Paramount Capital Investments LLC | Corporate Officer/Principal | ||
PolaRx Biopharmaceuticals
PolaRx Biopharmaceuticals Miscellaneous Commercial ServicesCommercial Services Part of Swedish Orphan Biovitrum AB, PolaRx Biopharmaceuticals is a company that manufactures TriOxide drugs for the treatment of leukemia and other cancers. The company is based in New York, NY. The company was founded by Fred H. Mermelstein, Peter Morgan Kash, Raymond P. Warrell. PolaRx Biopharmaceuticals was acquired by CTI BioPharma Corp., part of Swedish Orphan Biovitrum AB from June 27, 2023 on January 13, 2000 for $17.50 million. | Miscellaneous Commercial Services | Founder | |
Orion Biomedical Gp LLC | Corporate Officer/Principal | ||
Jordan Heart Foundation | Chairman | ||
CORREVIO PHARMA CORP. | Pharmaceuticals: Major | Chairman | |
FENNEC PHARMACEUTICALS INC. | Pharmaceuticals: Major | Director/Board Member | |
University of Medicine & Dentistry of New Jersey | College/University | Doctorate Degree | |
The University of Colorado | College/University | Doctorate Degree | |
Rutgers State University of New Jersey | College/University | Doctorate Degree | |
Javelin Pharmaceuticals, Inc.
Javelin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Javelin Pharmaceuticals, Inc. develops pharmaceutical drugs. It is a specialty pharmaceutical company that applies innovative proprietary technologies to develop new drugs and improved formulations of existing drugs that target current unmet and underserved medical market. The company's product candidates address the acute moderate-to-severe pain medication market segment. It has three late stage product candidates in development: Dyloject (diclofenac sodium, injectable), Rylomine (intranasal morphine) and PMI-150 (intranasal ketamine). The company was founded on February 23, 1998 and is headquartered in Cambridge, MA. | Pharmaceuticals: Major | Founder | |
Indiana University | College/University | Corporate Officer/Principal | |
Nexstar, Inc.
Nexstar, Inc. Miscellaneous Commercial ServicesCommercial Services Nexstar, Inc. operates as a business networking organization. It delivers comprehensive business training, systems, and coaching to independent home service plumbing, heating, air conditioning, and electrical professionals. The company was founded by Frank J. Blau Jr. in November 1992 and is headquartered in St. Paul, MN. | Miscellaneous Commercial Services | Chief Tech/Sci/R&D Officer | |
MERCK & CO., INC. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
ADHERA THERAPEUTICS, INC. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
Thermo BioStar, Inc.
Thermo BioStar, Inc. Medical SpecialtiesHealth Technology Part of Abbott Laboratories, Thermo BioStar, Inc. develops, manufactures, and markets high performance, rapid diagnostic tests. The company is based in Louisville, CO. Thermo BioStar was acquired by Alere, Inc. from Thermo Electron Corp. on October 03, 2005 for $52.50 million. | Medical Specialties | Corporate Officer/Principal | |
AI Proteins, Inc.
AI Proteins, Inc. Pharmaceuticals: MajorHealth Technology AI Proteins, Inc. is a biotech company based in Andover, MA. AI Proteins is focused on re-imagining protein therapeutics by designing entirely new proteins using an AI-based approach and a high-throughput drug discovery platform. The company's platform enables the development of inexpensive, durable, and highly specific proteins optimized for specific therapeutic applications. These proteins have the potential for oral delivery and can dramatically accelerate the development of lead therapeutic candidates ready for IND-enabling studies. The company was founded by Marc A. Cohen and Christopher Bahl. Noah D. Beerman has been the CEO of the company since 2023. | Pharmaceuticals: Major | Director/Board Member |
Statistieken
Internationaal
Verenigde Staten | 25 |
Canada | 2 |
Sectoraal
Health Technology | 13 |
Commercial Services | 5 |
Consumer Services | 5 |
Health Services | 2 |
Operationeel
Director/Board Member | 17 |
Chief Tech/Sci/R&D Officer | 6 |
Founder | 6 |
Corporate Officer/Principal | 4 |
Doctorate Degree | 3 |
Sterkste connecties
Insiders | |
---|---|
Fred H. Mermelstein | 16 |
Barry A. Polisky | 11 |
Julia Novina | 3 |
Carl Novina | 3 |
Tom Erickson | 1 |
Drew Dennison | 1 |
Todd Kaloudis | 1 |
- Beurs
- Insiders
- Sandage Bobby
- Bedrijfsconnecties